Appili Therapeutics's EBIT is $-5.9M, below the Healthcare sector average of $1.9T.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
Appili Therapeutics (APLI.TO) currently reports a EBIT of $-5.9M as of June 2026. That compares with $-32K in the prior-year period — down 18364.8% year over year. That is below the Healthcare sector average of $1.9T. Use the charts on this page to explore Appili Therapeutics's EBIT history and peer comparisons.
Appili Therapeutics's EBIT decreased from $-32K to $-5.9M — a 18364.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Appili Therapeutics's EBIT of $-5.9M is lower than the Healthcare sector average of $1.9T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Appili Therapeutics reported $-5.9M in EBIT as of June 2026. That compares with $-32K in the prior-year period — down 18364.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $-5.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.9T. From there, open related valuation or income-statement pages for Appili Therapeutics, and consider following APLI.TO for alerts when major investors trade the stock.